← Back to patent-cliff list
Levofloxacin/Ketorolac Tromethamine
Tier C — Watch / tradeLevofloxacin/Ketorolac Tromethamine
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Bacterial DNA gyrase, TOP2, COX-2, COX-1
Indications (approved)：细菌性结膜炎
Regional status
US
-
EU
Phase II
2021-11-05
China
-
2021-01-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Levofloxacin/Ketorolac Tromethamine?
Approved indications include: 细菌性结膜炎.
When does the Levofloxacin/Ketorolac Tromethamine patent expire?
No public expiry year is available for Levofloxacin/Ketorolac Tromethamine yet; this page updates once verified.
How do I get a quote for Levofloxacin/Ketorolac Tromethamine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21